FindTrial
Sign In

Investigation of the gut microbiome in patients with head and neck cancer (HNSCC) and analysis of the prognostic potential of response and tolerability of PD-1, PDL-1 immune checkpoint inhibitors in head and neck cancer

Investigation of the gut microbiome in patients with head and neck cancer (HNSCC) and analysis of the prognostic potential of response and tolerability of PD-1, PDL-1 immune checkpoint inhibitors in head and neck cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032481
Enrollment
50
Registered
2023-09-04
Start date
2023-09-15
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck carcinoma

Interventions

Group 1: Oncological patients with tumors in the head and neck region for whom therapy with an immune checkpoint inhibitor (PD-1, PD-L1) is planned

Sponsors

Lehrstuhl für Hals-Nasen-Ohrenheilkunde Universität Witten/Herdecke
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed head and neck carcinoma for which immune checkpoint inhibitor therapy (PD-1, PD-L1) is planned as part of treatment

Exclusion criteria

Exclusion criteria: Age under 18, lack of capacity to consent, and lack of patient consent

Design outcomes

Primary

MeasureTime frame
Response to immunocheckpoint inhibitor (PD-1, PD-L) therapy, occurrence of adverse immunotherapyrelated side effects under immuno-checkpoint inhibitor (PD-1, PD-L) therapy when restaging—

Secondary

MeasureTime frame
Applicability of cloud-based medical diagnostic software (BiomeOne®) in head and neck cancer.—

Countries

Germany

Contacts

Public ContactJonas Jae-Hyun Park

Lehrstuhl für Hals-Nasen-Ohrenheilkunde Universität Witten/Herdecke

jonas.park@uni-wh.de00492331-805549

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026